China · Advertising framework
Print advertising and advertorials for aesthetic treatments in China
General market orientation, not campaign clearance. Research scope and dates
Product and service rules
Medical institution advertising follows a narrow reviewed route
Legal requirement — paraphrased
The medical advertising measures require review and restrict ordinary institutional advertising to specified establishment information. They prohibit cure guarantees, treatment-effect rates and testimonial endorsements. Only legally established medical institutions may publish medical-service advertising through this route.
Sources: Measures for the Administration of Medical Advertising; Guidelines for Medical Advertising Supervision, 2025
Read the 2025 enforcement guidance alongside the underlying rules
Regulator guidance
The 2025 SAMR guidelines describe discretion for specified truthful institutional-information cases and minor changes. These are not a general exemption from medical advertising law or permission to promote treatments freely. Aesthetic ads creating appearance anxiety or targeting minors for non-therapeutic procedures raise specific enforcement concerns.
Sources: Guidelines for Medical Advertising Supervision, 2025
Apply the 2025 identification guidance to factual listings and health education
Regulator guidance
Applies when: Mainland Chinese medical institutions or their staff publish information about medical services.
The 2025 identification guidelines distinguish specified factual institutional information from advertising. Tabulated information on a third-party platform can fall outside advertising where it meets the guideline conditions and contains no subjective promotion.
Comparative claims, guarantees, promotional case stories and links from health education to the corresponding medical service can cross the boundary into advertising. A clinician’s name and professional affiliation in genuine educational material are not by themselves equivalent to a promotional endorsement.
Sources: SAMR / NHC / NATCM — Medical Advertising Identification Guidelines, 2025 · Medical Advertising Identification Guidelines sections 5–8
Channel rules
Check the complete consumer-facing message
Regulator guidance
Advertising must be truthful and clear. Review the accuracy of stated functions, benefits, provider details, prices and promises under the Advertising Law. Sector review requirements and prohibited claims continue to apply even when the advertiser identifies the commercial nature of a message.
Do not apply the ordinary-data threshold to health data
Regulator guidance
The CAC identifies medical and health information as sensitive personal information. Its under-100,000-person ordinary-data exemption excludes sensitive data. Subject to stated exemptions, a non-critical-infrastructure operator exporting sensitive information for fewer than 10,000 people must use the standard-contract or certification route; at least 10,000 requires a security assessment. Important data and critical-infrastructure operators have separate assessment triggers. Count people from 1 January and document the specific exemption, if any; an advertising consent checkbox does not establish a transfer mechanism.
Sources: Cross-border data provisions — official explanatory FAQ
Review at final printed size
Editorial recommendation
Approve the advertorial label, full layout and legibility at actual size. Check what must appear in the advertisement itself before moving details behind a QR code.
Campaign workflow
Aesthetic Medicine & Cosmetic Procedures: prepare the review
Editorial recommendation
Separate the procedure, clinic, device, cosmetic and prescription medicine in the offer. Check restrictions on injectables and other products even when the headline advertises a consultation. Review realistic outcomes, risks, patient images and time-limited offers.
Keep a traceable campaign decision
Editorial recommendation
Keep one review record linking the offer, local market status, claim evidence, exact creative, media settings and any regulatory or professional clearance. Record who checked each condition. Reopen the review when the offer, claim, source rule or execution changes.
Pre-publication checklist
- Separate the procedure, clinic, device, cosmetic and prescription medicine in the offer.
- Check restrictions on injectables and other products even when the headline advertises a consultation.
- Review realistic outcomes, risks, patient images and time-limited offers.
- Record product or provider eligibility before approving claims.
- Archive the final creative and its evidence, permissions and review decisions.
- Assign an owner for source updates, complaints and prompt withdrawal of inaccurate material.
Scope and unresolved questions
- Mainland only. Beijing TCM review, national online-retail display conditions, warning presentation and a cross-border data route are documented. Other provincial filing procedures, actual seller permissions, platform account rules, product-specific Chinese assets and the transfer facts still require review.
- This national baseline does not review every broadcaster rule, platform policy, regional licensing condition, promotion mechanic or data-transfer arrangement. No format-specific warning dimensions or durations should be inferred where none are supplied.
Research scope, introduction and dates
An aesthetic campaign in print campaigns in China can advertise a clinic while also implying claims about a procedure, device or prescription medicine. Separate those elements first, then review outcome images, risks and commercial pressure.
Printed advertisements must work at their final physical size. Review the advertorial label, required information, images and multipage layout together, including what stays on the page when a QR code points readers elsewhere.
General market orientation, not legal, regulatory or medical advice, a complete compliance plan or clearance of an advertisement. Actual requirements depend on the specific offer and campaign.
How to use this national baseline
Editorial overview
This framework combines researched national rules with editorial review steps. Mainland China only; Hong Kong, Macau and Taiwan are outside this pack. A visible channel workflow does not establish that the selected product or service may be advertised there. Read the category restrictions first.
The review date identifies when the cited provisions or regulator excerpts were checked. It does not mean that every local rule, exception, professional standard or platform policy has been reviewed.
Sources
- Measures for the Administration of Medical Advertising
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Guidelines for Medical Advertising Supervision, 2025
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- Advertising Law of the People’s Republic of China
Targeted source review; apply the cited provision to the exact offer and check subsequent changes before launch.
- SAMR / NHC / NATCM — Medical Advertising Identification Guidelines, 2025
Targeted review on 25 October 2026. This date does not certify the currency of other sources or resolve local and campaign-specific requirements.
- Cross-border data provisions — official explanatory FAQ
Follow-up review of the cited issue on 25 October 2026; scope and remaining conditions are recorded in the modules and review register.
From framework to action
Local expertise in China
Find support with medical and health marketing, marketing and sales advice, or organizing your business and coordinating projects in China.
Medical & health marketing
No partners listed in this category yet.
Marketing & sales advisory
No partners listed in this category yet.
Business & project coordination
No partners listed in this category yet.
Join the local partner directory
Would you like your company to be listed?
Talk to us about the terms of a listing. Leave your details and we will get in touch.